December 17, 2026
1:00 pm ET

How AI changed biopharma R&D in 2026, and what’s coming in 2027

An honest look back at where AI delivered for clinical operations and finance teams in 2026, and where it fell short. Plus, predictions for how it will transform the industry in 2027.

--
Days
--
Hours
--
Minutes
--
Seconds

Summary

2026 was the year biopharma R&D teams stopped asking, “Should I use AI?” and started asking, “How do I adopt and scale AI?” 

Join Condor Founder and CEO Jen Kyle, Ryan McGinn of CFGI, and two other industry experts for a candid look back and predictions for 2027.

‍

The panel will cover:

‍

  • What AI really changed in 2026: where it delivered for clinical operations and finance teams, where it fell short, and what the industry learned.
  • The innovations AI overshadowed: the new technologies and processes that deserve more attention.
  • Predictions for 2027: how AI will reshape biopharma R&D, and what teams should do now to prepare.
  • Live Q&A: bring your questions for the panel.

‍

The session opens with a 45-minute panel discussion, followed by 15 minutes of audience Q&A.

Speakers

Jen Kyle
CEO and Founder, Condor
Ryan McGinn
Director, FP&A Advisory, CFGI

Register for the webinar

2026-12_WEBINAR_AI-In-Biopharma-2027
How AI changed biopharma R&D in 2026, and what’s coming in 2027

Watch on-demand

On-demand recording

Catch Investigator Grant Discrepancies, Budget Drift, and Accrual Risk with AI

Watch the on-demand session to see how AI can catch investigator grant and site invoice discrepancies, surface sites spending ahead of or behind plan, and flag accrual and forecast risks before period-end.

On-demand recording

Clinical Finance AI Agent: Get the "why" behind the numbers, in seconds

See how Condor's newly launched Clinical Finance AI Agent explains a forecast variance in seconds, then builds the what-if scenario for you.

On-demand recording

Reimagining CRO Change Order Management with AI

CROs build change orders for months, then give you two weeks to review. Watch a Phase 3 change order analyzed end to end — hidden unit price increases, retroactive work, and the questions to ask before you approve.